Israeli pharmaceutical company "Bonus Bio Group" announced the success of its COVID-19 drug, achieving a 100% success rate among the first 10 patients involved in its clinical trials, according to the "Jerusalem Post" on Saturday. The trials were conducted at the "Rambam" health care center in Haifa.
According to the newspaper, the drug proved effective on patients aged between 45 and 75, all of whom were experiencing severe symptoms of infection. It was reported that 90% of these patients had other illnesses in addition to COVID-19. Data from the trials showed a 40% reduction in lung inflammation after receiving treatment, decreasing to 1% after five days. Additionally, the patients demonstrated improved respiratory function, with blood oxygen saturation levels increasing to 95%.
This drug comes alongside the emergence of other COVID-19 treatments around the world, suggesting a potentially nearing end to the pandemic threat. New trials conducted by researchers from the United States and Australia showed promising results, indicating the possibility of a "treatment" for COVID-19 that is effective by 99.9% for patients with severe symptoms.
What distinguishes this drug, which is administered via injection, is that its active ingredient can be stored at room temperature and requires only small doses according to the patient's needs. It is also capable of treating all viruses within the coronavirus family, including the original SARS virus (SARS-CoV-1) as well as SARS-CoV-2 and MERS, along with any new variants that may emerge, as it targets the "gene responsible for the virus directly," according to Australian researcher and trial participant Professor Nigel McMillan.
